Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
Open Access
- 6 February 2017
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 116 (6), 802-810
- https://doi.org/10.1038/bjc.2017.8
Abstract
Background: When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we developed a panel to use in ultra-deep sequencing to identify such mutations in cfDNA. Methods: Our panel (‘SiRe’) covers 568 mutations in six genes (EGFR, KRAS, NRAS, BRAF, cKIT and PDGFRα)involved in non-small-cell lung cancer (NSCLC), gastrointestinal stromal tumour, colorectal carcinoma and melanoma. We evaluated the panel performance in three steps. First, we analysed its analytical sensitivity on cell line DNA and by using an artificial reference standard with multiple mutations in different genes. Second, we analysed cfDNA from cancer patients at presentation (n=42), treatment response (n=12) and tumour progression (n=11); all patients had paired tumour tissue and cfDNA previously genotyped with a Taqman-derived assay (TDA). Third, we tested blood samples prospectively collected from NSCLC patients (n=79) to assess the performance of SiRe in clinical practice. Results: SiRe had a high analytical performance and a 0.01% lower limit of detection. In the retrospective series, SiRe detected 40 EGFR, 11 KRAS, 1 NRAS and 5 BRAF mutations (96.8% concordance with TDA). In the baseline samples, SiRe had 100% specificity and 79% sensitivity relative to tumour tissue. Finally, in the prospective series, SiRe detected 8.7% (4/46) of EGFR mutations at baseline and 42.9% (9/21) of EGFR p.T790M in patients at tumour progression. Conclusions: SiRe is a feasible NGS panel for cfDNA analysis in clinical practice.Keywords
This publication has 28 references indexed in Scilit:
- ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer PatientsClinical Cancer Research, 2016
- BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitorsMelanoma Research, 2015
- Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor–Positive Metastatic Breast CancerClinical Chemistry, 2015
- Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002Clinical Cancer Research, 2014
- Comprehensive molecular profiling of lung adenocarcinomaNature, 2014
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- Assuring the quality of next-generation sequencing in clinical laboratory practiceNature Biotechnology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Targeted therapies in gastrointestinal stromal tumorsSeminars in Diagnostic Pathology, 2008